308 related articles for article (PubMed ID: 9485028)
1. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
2. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.
Darrow TL; Slingluff CL; Seigler HF
J Immunol; 1989 May; 142(9):3329-35. PubMed ID: 2785141
[TBL] [Abstract][Full Text] [Related]
3. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.
Jerome KR; Barnd DL; Bendt KM; Boyer CM; Taylor-Papadimitriou J; McKenzie IF; Bast RC; Finn OJ
Cancer Res; 1991 Jun; 51(11):2908-16. PubMed ID: 1709586
[TBL] [Abstract][Full Text] [Related]
5. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
[TBL] [Abstract][Full Text] [Related]
6. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.
Crowley NJ; Slingluff CL; Darrow TL; Seigler HF
Cancer Res; 1990 Feb; 50(3):492-8. PubMed ID: 2404572
[TBL] [Abstract][Full Text] [Related]
7. Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line.
Ware CF; Krangel MS; Pious D; Burakoff SJ; Strominger JL
J Immunol; 1983 Sep; 131(3):1312-7. PubMed ID: 6193184
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic T cell clones against human autologous cancers: analysis of target antigen and the mechanism of specific target cell destruction.
Kikuchi K; Okubo M; Sato T; Sato N
Princess Takamatsu Symp; 1988; 19():303-13. PubMed ID: 3269362
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones.
Perez SA; Sotiropoulou PA; Sotiriadou NN; Mamalaki A; Gritzapis AD; Echner H; Voelter W; Pawelec G; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2002 Jan; 50(11):615-24. PubMed ID: 11807625
[TBL] [Abstract][Full Text] [Related]
10. Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary cancer cells.
Sato T; Sato N; Takahashi S; Koshiba H; Kikuchi K
Cancer Res; 1986 Sep; 46(9):4384-9. PubMed ID: 3488124
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells.
Ioannides CG; Freedman RS; Platsoucas CD; Rashed S; Kim YP
J Immunol; 1991 Mar; 146(5):1700-7. PubMed ID: 1704404
[TBL] [Abstract][Full Text] [Related]
12. Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.
Mimura K; Kono K; Southwood S; Fikes J; Takahashi A; Miyagawa N; Sugai H; Fujii H
Cancer Immunol Immunother; 2006 Nov; 55(11):1358-66. PubMed ID: 16435129
[TBL] [Abstract][Full Text] [Related]
13. In vitro human cytotoxic T cell responses against influenza A virus can be induced and selected by synthetic peptides.
Martinon F; Gomard E; Hannoun C; Lévy JP
Eur J Immunol; 1990 Oct; 20(10):2171-6. PubMed ID: 2242754
[TBL] [Abstract][Full Text] [Related]
14. Her-2/ neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction.
Dionne SO; Myers CE; Smith MH; Lake DF
Cancer Immunol Immunother; 2004 Apr; 53(4):307-14. PubMed ID: 14605764
[TBL] [Abstract][Full Text] [Related]
15. In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line.
Santegoets SJ; Schreurs MW; Masterson AJ; Liu YP; Goletz S; Baumeister H; Kueter EW; Lougheed SM; van den Eertwegh AJ; Scheper RJ; Hooijberg E; de Gruijl TD
Cancer Immunol Immunother; 2006 Dec; 55(12):1480-90. PubMed ID: 16468034
[TBL] [Abstract][Full Text] [Related]
16. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas.
Cordon-Cardo C; Fuks Z; Drobnjak M; Moreno C; Eisenbach L; Feldman M
Cancer Res; 1991 Dec; 51(23 Pt 1):6372-80. PubMed ID: 1933900
[TBL] [Abstract][Full Text] [Related]
17. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
Gückel B; Stumm S; Rentzsch C; Marmé A; Mannhardt G; Wallwiener D
Cancer Immunol Immunother; 2005 Feb; 54(2):129-40. PubMed ID: 15365776
[TBL] [Abstract][Full Text] [Related]
18. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.
Bacus SS; Stancovski I; Huberman E; Chin D; Hurwitz E; Mills GB; Ullrich A; Sela M; Yarden Y
Cancer Res; 1992 May; 52(9):2580-9. PubMed ID: 1373672
[TBL] [Abstract][Full Text] [Related]
19. Establishment of human cytotoxic T cell lines specific for human adult T cell leukemia virus-bearing cells.
Kannagi M; Sugamura K; Sato H; Okochi K; Uchino H; Hinuma Y
J Immunol; 1983 Jun; 130(6):2942-6. PubMed ID: 6189906
[TBL] [Abstract][Full Text] [Related]
20. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.
Chen T; Tang XD; Wan Y; Chen L; Yu ST; Xiong Z; Fang DC; Liang GP; Yang SM
Neoplasia; 2008 Sep; 10(9):977-86. PubMed ID: 18714399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
